Selection of non-steroidal anti-inflammatory drug and treatment regimen for XXXX mustard-induced cutaneous lesions.

@entity1707 @entity7674 @entity3522 @entity2951 @entity2033 @entity2632 @entity6914 @entity599 @entity130 @entity479
UNASSIGNED: The inflammatory process plays an important role in @entity599 mustard ( @entity2033 ) injury and @entity2033 pathogenesis, suggesting that anti-inflammatory treatments applied as soon as possible following @entity130 may reduce tissue damage and accelerate healing. This study used the @entity2033 dermal weanling @entity1707 model to investigate the efficacy of two non-steroidal anti-inflammatory drugs, @entity2951 and @entity3522 , when applied in combination with the @entity479 , @entity6914 . The therapeutic regimen was also investigated with respect to initiation of treatment post-exposure, frequency and duration. Yorkshire-cross @entity1707 were randomly assigned to experimental groups, corresponding to all combinations of treatment ( @entity2951 with @entity6914 or @entity3522 with @entity6914 ), onset time (1, 2 or 4   h post-exposure), treatment duration (1, 3 or 5 days) and frequency of applications (2, 3 or 4 per day). For each animal, two sites on the ventral abdomen were exposed to 400    L of neat @entity2033 for 8   min to achieve superficial dermal (SD) lesions and two sites were exposed to 400    L neat @entity2033 for 30   min to achieve deep @entity7674 . Each treatment regimen was tested against a SD and a @entity130 . Untreated SD and @entity2632 lesion sites served as within-animal controls. Assessments, up to one week post-challenge, included digital photographs, clinical assessments (lesion size measurements and modified Draize scoring), transepidermal water loss (TEWL), reflectance colorimetry and histopathologic evaluations that included an estimate for @entity130 and wound healing parameters. @entity3522 plus @entity6914 treatment resulted in significant reductions in lesion contracture and modified Draize scores, increased barrier function (decreased TEWL), and increased healing as determined by histopathology for both SD and @entity130 when compared with untreated sites and sites treated with @entity2951 plus @entity6914 . An increased duration of treatment from 1 to 5 days was most commonly associated with decreased clinical assessment and histopathological severity scores. Therefore, a combination of @entity3522 and @entity6914 application, when administered for at least five days, shows promise in ameliorating @entity2033 -induced lesions.
